NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) between August 2, 2023 to August 8, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Leandro Alvarez v. Pacira BioSciences, Inc., et al. (Case No. 2:25-cv-00322) has been commenced in the United States District Court for th ...

Shares of Pacira BioSciences (PCRX) gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company unveiled a five-year growth strategy aimed at accelerating its transformation into an innovative biopharmaceutical company and establishing itself as a leader in musculoskeletal pain and related areas. This has also likely contributed to the stock price rally.PCRX’s Preliminary Q4 2024 ResultsExparel’s net p ...

Earnings and Revenue Expectations - The specialty drugmaker is expected to post quarterly earnings of $0 83 per share, representing a year-over-year change of -6 7% [1] - Revenues are expected to be $178 98 million, down 1 3% from the year-ago quarter [1] - Empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements [1] Pacira (PCRX) Stock Performance and Estimates - The consensus EPS estimate for Pacira has been revised 0 6% lower over the last 30 days [2] - Pacira shares ended the last trading session 11 1% higher at $20 64, with a higher-than-average trading volume [3] - The stock had previously experienced a 6 2% loss over the past four weeks [3] - The sudden rise in stock price followed better-than-expected preliminary fourth-quarter 2024 sales figures and the unveiling of a five-year growth strategy [4] Industry and Peer Comparison - Pacira is a member of the Zacks Medical - Biomedical and Genetics industry [2] - Travere Therapeutics (TVTX), another stock in the same industry, finished the last trading session 4 8% lower at $18 09 but has returned 6 1% over the past month [2] - Travere's consensus EPS estimate for the upcoming report has changed -7 6% over the past month to -$0 61, representing a year-over-year change of +47 4% [5] - Travere currently holds a Zacks Rank of 2 (Buy) [5]

Core Viewpoint - Pacira BioSciences, Inc. is focused on transforming into an innovative biopharmaceutical organization with a five-year growth plan aimed at becoming a leader in musculoskeletal pain management, reporting preliminary unaudited revenue of $701.0 million for 2024, up from $675.0 million in 2023 [1][2]. Group 1: Financial Performance - Preliminary unaudited total revenue for 2024 is reported at $701.0 million, an increase of 3.7% from $675.0 million in 2023 [1]. - Fourth quarter net product sales for EXPAREL reached $147.7 million in 2024, compared to $143.9 million in 2023, with volume growth and a price increase partially offset by a shift in vial mix and discounting [8]. - Full-year EXPAREL net product sales totaled $549.0 million in 2024, up from $538.1 million in 2023, driven by a 4% average daily volume growth [8]. Group 2: Growth Strategy - The company aims to achieve five objectives by 2030 under its "5x30" plan, focusing on growth, operational excellence, and addressing unmet patient needs in musculoskeletal pain [2]. - Pacira is committed to expanding its clinical pipeline with five novel programs in development and establishing five partnerships, including pipeline and commercial agreements [7]. Group 3: Product Performance - Fourth quarter ZILRETTA net product sales were $33.1 million in 2024, up from $28.7 million in 2023, while iovera° net product sales increased to $6.5 million from $6.0 million in the same period [8]. - Full-year ZILRETTA net product sales reached $118.1 million in 2024, compared to $111.1 million in 2023, and iovera° net product sales were $22.8 million, up from $19.7 million [8]. Group 4: Market Position - Pacira has treated more than three million patients annually and is experiencing a double-digit compounded annual growth rate in product revenue [7]. - The company is positioned to extend its leadership in non-opioid pain management with a best-in-class commercial portfolio generating significant cash flow [2].

Pacira BioSciences (PCRX) announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. Please note that this hand-held medical device was added to Pacira’s portfolio following the acquisition of MyoScience.The iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis. This technique uses targeted cold therapy to temporarily disrupt a nerve' ...

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a ...

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a ...

PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About PaciraPacira delivers innovative, non-opioid pain therapies to ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Pacira BioSciences (PCRX) announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable suspension), ensuring protection against generics in the market through 2044. The ‘940 patent is the first from a new family of patents related to Exparel produced by Pacira’s enhanced large-scale manufacturing process in San Diego, which received FDA approval in February 2024.Exparel is Pacira’s flagship pain-manage ...